U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06983028) titled 'Atacicept in Multiple Glomerular Diseases' on May 13.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
pMN
IgAN
Nephrotic Syndrome
MCD
FSGS
Intervention:
DRUG: Atacicept
Atacicept 150 mg SC QW via pre-filled syringe
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vera Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....